JP7330893B2 - 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法 - Google Patents

短時間作用型ヘパリンベースの抗凝集剤化合物及び方法 Download PDF

Info

Publication number
JP7330893B2
JP7330893B2 JP2019549419A JP2019549419A JP7330893B2 JP 7330893 B2 JP7330893 B2 JP 7330893B2 JP 2019549419 A JP2019549419 A JP 2019549419A JP 2019549419 A JP2019549419 A JP 2019549419A JP 7330893 B2 JP7330893 B2 JP 7330893B2
Authority
JP
Japan
Prior art keywords
ost
groups
sulfation
idoa2s
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510119A5 (enExample
JP2020510119A (ja
Inventor
リウ ジエン
ワン チャンジェ
ポ－ホン、シェイ
シュウ ヤングメイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2020510119A publication Critical patent/JP2020510119A/ja
Publication of JP2020510119A5 publication Critical patent/JP2020510119A5/ja
Priority to JP2023129964A priority Critical patent/JP7702454B2/ja
Application granted granted Critical
Publication of JP7330893B2 publication Critical patent/JP7330893B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019549419A 2017-03-10 2018-03-12 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法 Active JP7330893B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023129964A JP7702454B2 (ja) 2017-03-10 2023-08-09 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469643P 2017-03-10 2017-03-10
US62/469,643 2017-03-10
PCT/US2018/021986 WO2018165656A1 (en) 2017-03-10 2018-03-12 Short-acting heparin-based anticoagulant compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023129964A Division JP7702454B2 (ja) 2017-03-10 2023-08-09 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法

Publications (3)

Publication Number Publication Date
JP2020510119A JP2020510119A (ja) 2020-04-02
JP2020510119A5 JP2020510119A5 (enExample) 2021-04-08
JP7330893B2 true JP7330893B2 (ja) 2023-08-22

Family

ID=63449042

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019549419A Active JP7330893B2 (ja) 2017-03-10 2018-03-12 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法
JP2023129964A Active JP7702454B2 (ja) 2017-03-10 2023-08-09 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023129964A Active JP7702454B2 (ja) 2017-03-10 2023-08-09 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法

Country Status (5)

Country Link
US (2) US11903963B2 (enExample)
EP (1) EP3579897A4 (enExample)
JP (2) JP7330893B2 (enExample)
CN (2) CN110446511B (enExample)
WO (1) WO2018165656A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
EP3691653B1 (en) 2017-11-03 2025-03-12 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
EP3810152A4 (en) 2018-06-20 2022-04-27 The University of North Carolina at Chapel Hill CELL PROTECTION METHODS AND COMPOSITIONS
MX2021008479A (es) 2019-01-15 2021-10-13 Optimvia Llc Enzimas dependientes de aril sulfato modificadas por ingenieria genetica.
CA3144968A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides
JP2023501568A (ja) * 2019-11-13 2023-01-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果
US20250154290A1 (en) * 2022-02-17 2025-05-15 Kyushu University, National University Corporation Recombinant heparin-like substance and method for producing the same
CN115417937B (zh) * 2022-08-12 2023-06-06 山东大学 一种含双抗凝血酶结合序列的肝素十二糖及其制备方法与应用
CN116120484B (zh) * 2022-09-01 2024-11-08 山东大学 一种抗凝血肝素寡糖苯联二聚体及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035787A1 (en) 2007-07-23 2009-02-05 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
WO2012116048A1 (en) 2011-02-22 2012-08-30 Rensselaer Polytechnic Institute Single step heparosan n-deacetylation and depolymerization for making bioengineered heparin
US20120322114A1 (en) 2005-05-12 2012-12-20 Rensselaer Polytechnic Institute Enzymatic synthesis of sulfated polysaccharides
US20130296540A1 (en) 2010-12-23 2013-11-07 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
JP2016523535A (ja) 2013-06-17 2016-08-12 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 可逆的ヘパリン分子、その製法及びその使用方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1232939B (it) 1987-11-06 1992-03-10 Opocrin Spa Eparan solfato caratterizzato da elevata attivita' antitrombotica, elevata biodisponibilita', assenza di attivita' anticoagulante; suo processo di estrazione da organi e da tessuti e relative composizioni farmaceutiche
US4865870A (en) 1988-07-07 1989-09-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5378829A (en) 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
WO1993005167A1 (en) 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
IT1260137B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
JP3818676B2 (ja) 1994-07-22 2006-09-06 生化学工業株式会社 ヘパラン硫酸６−ｏ−硫酸基転移酵素
IT1271057B (it) 1994-11-04 1997-05-26 Inalco Spa Polisaccaridi aventi un elevato contenuto di acido iduronico
JP3672359B2 (ja) 1995-07-24 2005-07-20 生化学工業株式会社 ヘパラン硫酸 ２−ｏ−硫酸基転移酵素
JP3713276B2 (ja) 1995-09-29 2005-11-09 バイオマリン ファーマシューティカル インコーポレイテッド 炎症反応の軽減のためのヘパリナーゼの使用
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6861254B1 (en) 1997-10-24 2005-03-01 Massachusetts Institute Of Technology Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
US8088604B2 (en) 1998-04-02 2012-01-03 The Board Of Regents Of The University Of Oklahoma Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6255088B1 (en) 1999-05-11 2001-07-03 The Scripps Research Institute Enzymatic sulfation of biomolecules
US6977248B1 (en) * 1999-08-25 2005-12-20 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US7101859B2 (en) 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
CA2698561C (en) 2000-07-07 2012-07-10 Seikagaku Corporation Hyaluronic acid oligosaccharide fractions and drugs containing the same
CA2441984A1 (en) 2001-03-28 2002-10-10 Massachusetts Institute Of Technology Methods of 6-o-sulfating polysaccharides and 6-o-sulfated polysaccharide preparations
WO2002089742A2 (en) 2001-05-08 2002-11-14 The Board Of Regents Of The University Of Oklahoma Heparin/heparosan synthase and methods of making and using same
PT1401853E (pt) 2001-05-25 2010-12-07 Univ Duke Modulador de oligonucleotídeos
WO2003018598A2 (en) 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
US7531338B2 (en) * 2002-07-05 2009-05-12 The University Of North Carolina At Chapel Hill Purified and isolated heparan sulfate 3-O-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
GB0216861D0 (en) 2002-07-19 2002-08-28 Univ Birmingham Saccharide libraries
WO2004017910A2 (en) 2002-08-23 2004-03-04 Neose Technologies, Inc. Total synthesis of heparin
WO2005014619A2 (en) 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US20040259142A1 (en) 2003-06-04 2004-12-23 Imperial College Innovations Limited Products and methods
EP1529785B1 (en) 2003-10-24 2011-03-16 3M Innovative Properties Company Aqueous dispersions of polytetrafluoroethylene particles
US7655445B2 (en) 2003-11-12 2010-02-02 Massachusetts Institute Of Technology Methods for synthesis of sulfated saccharides
WO2005118609A2 (en) 2004-05-26 2005-12-15 California Institute Of Technology Small molecule stimulators of neuronal growth
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US20060229276A1 (en) 2004-07-28 2006-10-12 Magnus Hook Use of glycosoaminoglycans for the prevention and treatment of sepsis
WO2007023867A1 (ja) 2005-08-24 2007-03-01 Seikagaku Corporation 新規コンドロイチン画分製造方法
EP2447285A3 (en) 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US20110009361A1 (en) 2007-12-21 2011-01-13 Glycan Biosciences Pty Ltd Design and selection of medicaments that modulate the function and activity of interleukin 13
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
WO2010087207A1 (ja) 2009-02-02 2010-08-05 大塚化学株式会社 低分子量多硫酸化ヒアルロン酸誘導体及びこれを含有する医薬
SG175133A1 (en) 2009-04-09 2011-12-29 Univ North Carolina Methods of treating edema related to ischemia-reperfusion
US20110054236A1 (en) 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
WO2011038047A1 (en) 2009-09-23 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
NZ611316A (en) 2010-12-01 2014-12-24 Univ Australian Histone inhibition
US8519189B2 (en) 2011-06-01 2013-08-27 University Of British Columbia Polymers for reversing heparin-based anticoagulation
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
EP3691653B1 (en) 2017-11-03 2025-03-12 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
EP3810152A4 (en) 2018-06-20 2022-04-27 The University of North Carolina at Chapel Hill CELL PROTECTION METHODS AND COMPOSITIONS
JP2023501568A (ja) 2019-11-13 2023-01-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果
JP7670561B2 (ja) 2021-06-28 2025-04-30 日本航空電子工業株式会社 コネクタ

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322114A1 (en) 2005-05-12 2012-12-20 Rensselaer Polytechnic Institute Enzymatic synthesis of sulfated polysaccharides
US20090035787A1 (en) 2007-07-23 2009-02-05 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
US20130296540A1 (en) 2010-12-23 2013-11-07 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
WO2012116048A1 (en) 2011-02-22 2012-08-30 Rensselaer Polytechnic Institute Single step heparosan n-deacetylation and depolymerization for making bioengineered heparin
JP2016523535A (ja) 2013-06-17 2016-08-12 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 可逆的ヘパリン分子、その製法及びその使用方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biochemistry，2008年，47(21)，5774-5783
Chem, Eur. J., ，2001年，7(22)，4821-4834
Nat. Chem. Biol.，2008年，4(3)，200-202
Proc Natl Acad Sci USA，2012年，Vol.109, No.14，p.5265-5270
Science，2011年，Vol.334，p.498-501
The Journal of Biological Chemistry，2010年，Vol.285, No.44，p.34240-34249

Also Published As

Publication number Publication date
WO2018165656A1 (en) 2018-09-13
JP7702454B2 (ja) 2025-07-03
US11903963B2 (en) 2024-02-20
CN110446511B (zh) 2024-04-02
CN110446511A (zh) 2019-11-12
JP2023166387A (ja) 2023-11-21
CN116622006A (zh) 2023-08-22
JP2020510119A (ja) 2020-04-02
CN116622006B (zh) 2025-05-30
EP3579897A1 (en) 2019-12-18
US20210137967A1 (en) 2021-05-13
US20240066048A1 (en) 2024-02-29
EP3579897A4 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
JP7702454B2 (ja) 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法
US7601488B2 (en) Hyaluronic acid oligosaccharide fractions and drugs containing the same
Linhardt 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity
Noti et al. Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans
JP7728547B2 (ja) 抗炎症作用を有する硫酸化オリゴ糖
TWI769176B (zh) 生合成肝素
Chandarajoti et al. The design and synthesis of new synthetic low‐molecular‐weight heparins
Wang et al. Investigation of the biological functions of heparan sulfate using a chemoenzymatic synthetic approach
US20190002596A1 (en) Sulfated heparin oligosaccharide and preparation method and application thereof
Liu et al. Synthesis of anticoagulant pentasaccharide fondaparinux via 3, 5-dimethyl-4-(2′-phenylethynylphenyl) phenyl glycosides
JP2010518251A (ja) ビオチンまたはビオチン誘導体との少なくとも１つの共有結合を含むヘパリン、これらの調製方法およびこれらの使用
Toida et al. Structural analysis of heparan sulfate and heparan sulfate oligosaccharides
JP4528898B2 (ja) ケモカイン受容体ｃｃｒ１０の発現誘導剤
O'Leary Chemical and Enzymatic Methods for the Analysis and Synthesis of Heparin and Heparan Sulfate
RU2848219C1 (ru) Биосинтетический гепарин
Zhang et al. Heparin mimetics as tools for modulation of biology and therapy
RU2760706C9 (ru) Биосинтетический гепарин
Joshi Chemical synthesis of 3-o-sulfated heparan sulfate oligosaccharides as diagnostic biomarkers and standards for exploring protein-carbohydrate interactions
Zong Explore the interaction of protein and synthetic heparan sulfate via a modular approach

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221223

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230809

R150 Certificate of patent or registration of utility model

Ref document number: 7330893

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150